Merck KGaA raises 2026 outlook after mixed third-quarter results
+1 new source since this summary was written
On November 12, Merck KGaA reported third-quarter net profit down 49.9% to €450 million, while sales rose 5.8% to €5.627 billion and EBITDA pre increased 0.8% to €1.682 billion. It lifted fiscal 2026 net sales guidance to €21.5 billion-€21.9 billion and EBITDA pre guidance to €6.2 billion-€6.4 billion, its third increase this year. The revised outlook includes the Bio-Techne acquisition, which Merck expects to complete in December 2026.
Why it matters
The higher guidance raises Merck KGaA’s stated fiscal 2026 earnings outlook, although the quarter also showed sharply lower reported profit. The company expects no US Mavenclad sales from November, creating a disclosed healthcare headwind as the Bio-Techne transaction proceeds.
Key facts
- 1Third-quarter net profit fell 49.9% to €450 million from €898 million a year earlier. rttnews.com
- 2Third-quarter sales increased 5.8% to €5.627 billion, including 5.1% organic growth and a 1.5% foreign-exchange contribution. rttnews.com
- 3Third-quarter EBITDA pre rose 0.8% to €1.682 billion from €1.669 billion, while organic EBITDA pre growth was approximately 0.4%. rttnews.com
- 4Merck KGaA now forecasts fiscal 2026 net sales of €21.5 billion-€21.9 billion and EBITDA pre of €6.2 billion-€6.4 billion. rttnews.com
- 5Merck’s US$11.3 billion purchase of Bio-Techne is expected to complete in December 2026. theedgemalaysia.com
Open questions
- reports an EBITDA pre margin of 18.5%, while reports 29.9% for the same quarter; the materials do not reconcile the difference.
- reports adjusted Q3 EPS as $2.32, while reports earnings per share before special items as €2.32, creating an unresolved currency discrepancy.
- describe opposite share-price reactions on the day.
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.